Research graph
References from Engineered Escherichia coli Nissle with an inducible phenylalanine degrading cassette and a multi-input kill switch. Local targets link to admitted publications; unresolved targets remain external evidence.
Emerging strategies for engineering Escherichia coli Nissle 1917-based therapeutics
10.1016/j.tips.2022.02.002 · 2022 · External reference
Engineered E. coli Nissle 1917 for the delivery of matrix-tethered therapeutic domains to the gut
10.1038/s41467-019-13336-6 · 2019 · External reference
Engineering a Novel Probiotic Toolkit in Escherichia coli Nissle 1917 for Sensing and Mitigating Gut Inflammatory Diseases
10.1021/acssynbio.4c00036 · 2024 · External reference
Developing a new class of engineered live bacterial therapeutics to treat human diseases
10.1038/s41467-020-15508-1 · 2020 · External reference
An engineered E. coli Nissle improves hyperammonemia and survival in mice and shows dose-dependent exposure in healthy humans
10.1126/scitranslmed.aau7975 · 2019 · External reference
The live biotherapeutic SYNB1353 decreases plasma methionine via directed degradation in animal models and healthy volunteers
10.1016/j.chom.2024.01.005 · 2024 · External reference
Recent advances of engineered probiotics for therapeutic applications
10.1016/j.bidere.2025.100039 · 2025 · External reference
Prospective and challenges of live bacterial therapeutics from a superhero Escherichia coli Nissle 1917
10.1080/1040841x.2022.2109405 · 2023 · External reference
Escherichia coli strain Nissle 1917-from bench to bedside and back: history of a special Escherichia coli strain with probiotic properties
10.1093/femsle/fnw212 · 2016 · External reference
Clinical use of E. coli Nissle 1917 in inflammatory bowel disease
10.1002/ibd.20377 · 2008 · External reference
Adaptive Strategies of the Candidate Probiotic E. coli Nissle in the Mammalian Gut
10.1016/j.chom.2019.02.005 · 2019 · External reference
Escherichia coli Nissle 1917 engineered to express Tum-5 can restrain murine melanoma growth
10.18632/oncotarget.20486 · 2017 · External reference
Engineered probiotics for local tumor delivery of checkpoint blockade nanobodies
10.1126/scitranslmed.aax0876 · 2020 · External reference
Engineering tumor-colonizing E. coli Nissle 1917 for detection and treatment of colorectal neoplasia
10.1038/s41467-024-44776-4 · 2024 · External reference
Intestinal probiotics E. coli Nissle 1917 as a targeted vehicle for delivery of p53 and Tum-5 to solid tumors for cancer therapy
10.1186/s13036-019-0189-9 · 2019 · External reference
Engineered E. coli Nissle 1917 for delivery of bioactive IL-2 for cancer immunotherapy
10.1038/s41598-023-39365-2 · 2023 · External reference
Engineered Escherichia coli for the in situ secretion of therapeutic nanobodies in the gut
10.1016/j.chom.2023.03.007 · 2023 · External reference
Engineered calprotectin-sensing probiotics for IBD surveillance in humans
10.1073/pnas.2221121120 · 2023 · External reference
Biomarker-responsive engineered probiotic diagnoses, records, and ameliorates inflammatory bowel disease in mice
10.1016/j.chom.2022.12.004 · 2023 · External reference
Incorporation of therapeutically modified bacteria into gut microbiota inhibits obesity
10.1172/jci72517 · 2014 · External reference
Designer probiotic-based living drugs for uric acid homeostasis control in hyperuricemic mice and rats
2025 · External reference
Development of a synthetic live bacterial therapeutic for the human metabolic disease phenylketonuria
10.1038/nbt.4222 · 2018 · External reference
Phase I Study of SYNB1891, an Engineered E. coli Nissle Strain Expressing STING Agonist, with and without Atezolizumab in Advanced Malignancies
10.1158/1078-0432.ccr-23-0118 · 2023 · External reference
Safety and pharmacodynamics of an engineered E. coli Nissle for the treatment of phenylketonuria: a first-in-human phase 1/2a study
10.1038/s42255-021-00430-7 · 2021 · External reference
Surveying the Genetic Design Space for Transcription Factor-Based Metabolite Biosensors: Synthetic Gamma-Aminobutyric Acid and Propionate Biosensors in E. coli Nissle 1917
10.3389/fbioe.2022.938056 · 2022 · External reference
A designed whole-cell biosensor for live diagnosis of gut inflammation through nitrate sensing
10.1016/j.bios.2020.112523 · 2020 · External reference
Genetic Circuits for Feedback Control of Gamma-Aminobutyric Acid Biosynthesis in Probiotic Escherichia coli Nissle 1917
10.3390/metabo14010044 · 2024 · External reference
Genetically Encoded Biosensors for Constrained Biological Functions in Probiotic Escherichia coli Nissle
10.1021/acssynbio.4c00747 · 2025 · External reference
Rational Design and Characterization of Nitric Oxide Biosensors in E. coli Nissle 1917 and Mini SimCells
10.1021/acssynbio.1c00223 · 2021 · External reference
Engineering ligand-specific biosensors for aromatic amino acids and neurochemicals
10.1016/j.cels.2021.10.006 · 2022 · External reference
Biocontainment of genetically modified organisms by synthetic protein design
10.1038/nature14121 · 2015 · External reference
Genetically stable CRISPR-based kill switches for engineered microbes
10.1038/s41467-022-28163-5 · 2022 · External reference
Advances in engineering genetic circuits for microbial biocontainment
2023 · External reference
Auxotrophy to Xeno-DNA: an exploration of combinatorial mechanisms for a high-fidelity biosafety system for synthetic biology applications
10.1186/s13036-018-0105-8 · 2018 · External reference
Multilayered genetic safeguards limit growth of microorganisms to defined environments
10.1093/nar/gku1378 · 2015 · External reference
Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10
10.1038/nbt840 · 2003 · External reference
Engineered probiotic Escherichia coli can eliminate and prevent Pseudomonas aeruginosa gut infection in animal models
10.1038/ncomms15028 · 2017 · External reference
Advanced and Safe Synthetic Microbial Chassis with Orthogonal Translation System Integration
10.1021/acssynbio.4c00437 · 2024 · External reference
Synthetic auxotrophy remains stable after continuous evolution and in coculture with mammalian cells
10.1126/sciadv.abf5851 · 2021 · External reference
A new approach for containment of microorganisms: dual control of streptavidin expression by antisense RNA and the T7 transcription system
10.1073/pnas.94.4.1059 · 1997 · External reference
A genetically engineered Escherichia coli that senses and degrades tetracycline antibiotic residue
10.1016/j.synbio.2018.05.001 · 2018 · External reference
Comparison of Kill Switch Toxins in Plant-Beneficial Pseudomonas fluorescens Reveals Drivers of Lethality, Stability, and Escape
10.1021/acssynbio.2c00386 · 2022 · External reference
Synthetic Cassettes for pH-Mediated Sensing, Counting, and Containment
10.1016/j.celrep.2020.02.033 · 2020 · External reference
Secure biosystems design in Saccharomyces cerevisiae establishes effective biocontainment strategies and mechanisms of escape
10.1128/aem.00741-25 · 2025 · External reference
Rational Design of Evolutionarily Stable Microbial Kill Switches
10.1016/j.molcel.2017.10.033 · 2017 · External reference
Deadman' and 'Passcode' microbial kill switches for bacterial containment
10.1038/nchembio.1979 · 2016 · External reference
Cas9-assisted biological containment of a genetically engineered human commensal bacterium and genetic elements
10.1038/s41467-024-45893-w · 2024 · External reference
Phenylketonuria
10.1038/s41572-021-00267-0 · 2021 · External reference
Pathogenesis of cognitive dysfunction in phenylketonuria: review of hypotheses
10.1016/j.ymgme.2009.10.016 · 2010 · External reference
The impact of phenylalanine levels on cognitive outcomes in adults with phenylketonuria: Effects across tasks and developmental stages
10.1037/neu0000336 · 2017 · External reference
Introduction of sapropterin dihydrochloride as standard of care in patients with phenylketonuria
10.1016/j.ymgme.2010.03.022 · 2010 · External reference
Formulation and PEGylation optimization of the therapeutic PEGylated phenylalanine ammonia lyase for the treatment of phenylketonuria
10.1371/journal.pone.0173269 · 2017 · External reference
Pegvaliase for the treatment of phenylketonuria: Results of a long-term phase 3 clinical trial program (PRISM)
10.1016/j.ymgme.2018.03.006 · 2018 · External reference
Evaluation of orally administered PEGylated phenylalanine ammonia lyase in mice for the treatment of Phenylketonuria
10.1016/j.ymgme.2011.06.016 · 2011 · External reference
Pegvaliase for the treatment of phenylketonuria: Final results of a long-term phase 3 clinical trial program
2024 · External reference
A Comprehensive Review of Pegvaliase, an Enzyme Substitution Therapy for the Treatment of Phenylketonuria
10.1177/1177392819857089 · 2019 · External reference
Cloning and sequencing of the pheP gene, which encodes the phenylalanine-specific transport system of Escherichia coli
10.1128/jb.173.12.3622-3629.1991 · 1991 · External reference
New insights into tetrahydrobiopterin pharmacodynamics from Pah enu1/2, a mouse model for compound heterozygous tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency
10.1016/j.bcp.2010.07.042 · 2010 · External reference
The ribosome binding site calculator
10.1016/b978-0-12-385120-8.00002-4 · 2011 · External reference
Next-generation biocontainment systems for engineered organisms
10.1038/s41589-018-0056-x · 2018 · External reference
Improvement of a synthetic live bacterial therapeutic for phenylketonuria with biosensor-enabled enzyme engineering
10.1038/s41467-021-26524-0 · 2021 · External reference
Recoded organisms engineered to depend on synthetic amino acids
10.1038/nature14095 · 2015 · External reference
Influence of Environmental Conditions on the Escape Rates of Biocontained Genetically Engineered Microbes
10.1021/acs.est.4c10893 · 2024 · External reference
Resilience of recombinant antibiotic resistance gene-containing plasmids against common cell culture disposal methods
10.1016/j.crmeth.2026.101430 · 2026 · External reference
Engineering E. coli strains using antibiotic-resistance-gene-free plasmids
2023 · External reference
Gut Colonization Mechanisms of Lactobacillus and Bifidobacterium: An Argument for Personalized Designs
10.1146/annurev-food-061120-014739 · 2021 · External reference
Tyrosine, phenylalanine, and catecholamine synthesis and function in the brain
10.1093/jn/137.6.1539s · 2007 · External reference
Blood phenylalanine reduction corrects CNS dopamine and serotonin deficiencies and partially improves behavioral performance in adult phenylketonuric mice
10.1016/j.ymgme.2017.10.009 · 2018 · External reference
Man made disease: clinical manifestations of low phenylalanine levels in an inadequately treated phenylketonuria patient and mouse study
10.1016/j.ymgme.2013.10.006 · 2013 · External reference
Pretreatment of mice with streptomycin provides a Salmonella enterica serovar Typhimurium colitis model that allows analysis of both pathogen and host
10.1128/iai.71.5.2839-2858.2003 · 2003 · External reference
Precolonized human commensal Escherichia coli strains serve as a barrier to E. coli O157:H7 growth in the streptomycin-treated mouse intestine
10.1128/iai.00059-09 · 2009 · External reference
Independent and tight regulation of transcriptional units in Escherichia coli via the LacR/O, the TetR/O and AraC/I1-I2 regulatory elements
10.1093/nar/25.6.1203 · 1997 · External reference
